Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipelineGilead's Strategic Acquisition of TubulisBy Sriparna RoyApril 7 (Reuters) - Gilead said on Tuesday it would acquire Germany-based Tubulis GmbH for up to $5 billion, as it looks to strengthen its cancer drugs pipeline. Tubulis' Drug PipelineLead Asset: TUB-040Tubulis' lead asset, TUB-040, which binds to NaPi2b, a protein found in certain cancer cells, is currently in early-stage development for a type of ovarian cancer and non-small cell lung cancer. Additional Experimental DrugsAnother experimental drug, TUB-030, is being studied across various solid tumor types. Financial Terms and Future OperationsGilead will acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash, payable at closing, and up to $1.85 billion in milestone payments. Tubulis also has a partnership with Bristol-Myers SquibbAfter the deal closes, expected in the second quarter, Tubulis will operate as an ADC research organization within Gilead.

Source: Economic Times April 07, 2026 12:37 UTC